Quanticsoft
Quanticsoft is recorded as a service provider in 7 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 7 of 7 trials · Latest update first
FILOCLL017-NEVOTAL: Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 alterations
Sponsor French Innovative Leukemia Organization (F.I.L.O.).
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
FILO-AML-01-MIVONU A single arm phase II study investigating the efficacy and safety of the addition of ivosidenib to oral azacitidine (Onureg®) in patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation, in complete remission after intensive chemotherapy. A study of the French AML Intergroup.
Sponsor French Innovative Leukemia Organization
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with RIchter syndrome as Frontline therapY
Sponsor French Innovative Leukemia Organization
- Start (EU)
- Latest update
- Estimated end
- Not reported
TAGVEN "Open label phase II study evaluating the efficacy and safety of the combination of tagraxofusp and venetoclax in treatment-naive blastic plasmacytoid dendritic cell neoplasm patients"
Sponsor French Innovative Leukemia Organization
- Start (EU)
- Latest update
- Estimated end
- Not reported
FILOCLL14 - STAIR : "Open-label, phase 2 study investigating the STop and restart Acalabrutinib In fRrail patients with previously untreated CLL (STAIR)"
Sponsor French Innovative Leukemia Organization
- Start (EU)
- Latest update
- Estimated end
- Not reported
FILOAML-RR-01-OGILAR: Open-label, phase 2 study investigating the efficacy and safety of the addition of oral-azacitidine to salvage treatment by gilteritinib in subjects ≥18 years of age with relapsed/refractory FLT3-mutated acute myeloid leukemia
Sponsor French Innovative Leukemia Organization
- Start (EU)
- Latest update
- Estimated end
- Not reported
Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously untreated symptomatic chronic lymphocytic leukemia (CLL). A phase II FILO trial
Sponsor French Innovative Leukemia Organization
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Quanticsoft?
The 2026-10-09 snapshot links Quanticsoft to 7 distinct CTIS trials. Recorded services include Electronic data capture. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Quanticsoft?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Quanticsoft conducted?
The linked trials record locations in 1 country, including France. These are trial locations, not confirmed office locations or countries where Quanticsoft delivered services.
What can this page tell me about Quanticsoft's trial experience?
Browse 7 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Quanticsoft. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Quanticsoft